Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Exercise Intervention to Support Recovery After Allogeneic Stem Cell Transplantation in Adults With Myeloid Blood Disorders (RESTART)

17 novembre 2026 aggiornato da: Miriam Götte, Universität Duisburg-Essen

RESTART - Cognitive, Physiological, and Immunological Effects of a Multimodal Exercise Intervention in Patients After Allogeneic Hematopoietic Stem Cell Transplantation

The goal of this clinical trial is to learn how a 12-week exercise intervention affects recovery after allogeneic stem cell transplantation in adults with a myeloid blood disorder. The main question is whether the exercise intervention helps maintain or improve thinking skills, especially attention, mental flexibility, and working memory, compared with usual care. The study will also look at physical function, quality of life, symptoms, activity levels, and clinical recovery.

After leaving the hospital following stem cell transplantation, participants will be randomly assigned to one of two groups. One group will receive the 12-week exercise intervention in addition to usual care. The other group will receive usual care without an additional RESTART exercise program during these 12 weeks.

Participants in the exercise group will complete three exercise sessions each week: one individual in-person session, one guided online session, and one home-based session.

The exercises may include endurance, strength, mobility, balance, coordination, and activities that combine movement with thinking tasks. The program will be adjusted to each participant's health, fitness, symptoms, and daily condition.

All participants will complete study assessments shortly before transplantation, at hospital discharge, and after the 12-week intervention or control period. Follow-up assessments will also take place 6 and 12 months after discharge, mainly using questionnaires and clinical information from routine care.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Germania, 45147
        • Reclutamento
        • University Hospital Essen
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 18 years of age or older
  • Scheduled to undergo a first allogeneic hematopoietic stem cell transplantation (HSCT) with an inpatient hospital stay for a myeloid blood disorder
  • Cleared by the treating physician to participate in physical exercise before and after HSCT
  • Able to move around independently or with the use of an assistive device
  • Sufficient German language skills to understand the study information and exercise instructions, report symptoms, and complete the study questionnaires
  • Able to understand the study and provide written informed consent
  • Able to take part in the supervised online exercise sessions, including access to an internet-enabled device and a sufficiently stable internet connection

Exclusion Criteria:

  • An acute medical condition that makes physical exercise unsafe, as determined by the treating physician
  • Cognitive or mental health problems that prevent safe participation in the exercise program or understanding of the study procedures
  • Pregnancy or plans to become pregnant during the 12-week study intervention
  • Insufficient German language skills to participate safely in the exercise program or to complete the study assessments
  • Participation in another structured exercise or training program that could affect the study results. Normal daily activities and self-directed physical activity are allowed.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Exercise Intervention Group

Participants assigned to this arm receive the 12-week RESTART exercise intervention in addition to usual medical, nursing, and supportive care after allogeneic hematopoietic stem cell transplantation.

Participants receive a 12-week individualized, multimodal exercise intervention in addition to usual care, consisting of three sessions per week: one individual in-person session (approximately 60 minutes), one live supervised online session (approximately 45 minutes), and one independently performed home-based session (approximately 30 minutes). Across the intervention, exercise content may include aerobic, resistance, mobility, balance, coordination, and cognitive-motor exercises. Training duration, intensity, exercise selection, and volume are individually adapted to the participant's medical condition, physical capacity, treatment-related symptoms, daily condition, and personal goals. In-person and online sessions are supervised by qualified exercise therapists; home-based exercises are individually selected and explained in advance, with an emphasis on low-risk, easily controllable exercises that can be performed safely without direct supervision.

Nessun intervento: Usual Care Control Group

Participants assigned to this arm receive usual medical, nursing, and supportive care during the 12-week control period. No additional RESTART exercise intervention is provided during this period. Medically indicated care and self-directed physical activity are not restricted.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Executive Function Composite Score From Hospital Discharge to 13 Weeks After Discharge
Lasso di tempo: Hospital discharge (T1) and 13 weeks after hospital discharge, following the 12-week intervention or control period (T2)

Executive function is assessed using a standardized composite score derived from performance on the Flanker Task (reaction time, error rate, and flanker effect), Trail Making Test Part B (completion time), and Digit Span Backward (score). Individual test measures are standardized and combined into a composite score representing executive function, including inhibitory control, cognitive flexibility, and working memory. Test measures are transformed as needed so that higher composite scores indicate better executive function.

Hospital discharge (T1) and 13 weeks after hospital discharge, following the 12-week intervention or control period (T2)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Global Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA)
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Global cognitive function is assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better global cognitive function.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Reaction Time Assessed by the OORTT 4 Positions Reaction Times
Lasso di tempo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Reaction time is assessed using the OORTT 4 Positions Reaction Times and reported in milliseconds (ms). Lower values indicate faster responses.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Inhibitory Control Assessed by the Flanker Task
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Inhibitory control is assessed using the Flanker Task. The primary task-specific outcome is the reaction-time-based flanker interference effect, calculated as the difference in mean reaction time between incongruent and congruent trials and expressed in milliseconds (ms). A smaller interference effect indicates better inhibitory control. Reaction time and error rate are additionally recorded as task performance parameters.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Cognitive Flexibility Assessed by Trail Making Test Part B
Lasso di tempo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Cognitive flexibility and task switching are assessed using Trail Making Test Part B. The outcome is completion time in seconds, with shorter completion times indicating better performance.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Working Memory Assessed by Digit Span Backward
Lasso di tempo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Working memory is assessed using Digit Span Backward. The outcome is the total score according to the standardized scoring procedure, with higher scores indicating better working-memory performance.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Static Balance Assessed by the 4-Stage Balance Test
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Static balance is assessed using the 4-Stage Balance Test, consisting of four progressively more difficult standing positions. Each position is held for up to 10 seconds. The outcome is the highest stage successfully maintained for 10 seconds, ranging from 0 to 4, with higher values indicating better static balance.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Maximum Isometric Handgrip Strength
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Maximum isometric handgrip strength is assessed using the CITEC Handheld Dynamometer Advanced Kit and expressed as peak force in Newtons (N). Three valid maximal trials are performed with the dominant hand, and the highest peak force is used for analysis. Higher values indicate greater handgrip strength.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in isometric knee flexor strength (hand-held dynamometry)
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Isometric knee flexor strength is assessed using the CITEC Handheld Dynamometer Advanced Kit and expressed as peak force in Newtons (N). Three valid maximal isometric knee extension trials are performed with the dominant leg, and the mean peak force of the three trials is used for analysis. Higher values indicate greater knee extensor strength.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Functional Lower-Extremity Performance Assessed by the 30-Second Sit-to-Stand Test
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Functional lower-extremity performance is assessed using the 30-Second Sit-to-Stand Test. The outcome is the number of complete sit-to-stand repetitions performed within 30 seconds. Higher values indicate better functional performance.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Peak Work Rate Assessed by the Steep Ramp Test
Lasso di tempo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Exercise capacity is assessed using the Steep Ramp Test performed on a cycle ergometer. The outcome is peak work rate (WRpeak), expressed in watts (W), achieved at the end of the test. Higher values indicate greater exercise capacity.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Perceived Cognitive Impairment Assessed by the FACT-Cog Version 3
Lasso di tempo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Perceived cognitive impairment is assessed using the Perceived Cognitive Impairments (PCI) subscale of the Functional Assessment of Cancer Therapy-Cognitive Function, Version 3 (FACT-Cog v3). The PCI score ranges from 0 to 72, with higher scores indicating better self-reported cognitive function and fewer perceived cognitive impairments.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Global Health Status and Quality of Life Assessed by the EORTC QLQ-C30
Lasso di tempo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Global health status and quality of life are assessed using the Global Health Status/Quality of Life scale of the EORTC QLQ-C30. Scores are transformed to a scale from 0 to 100 according to the EORTC scoring manual, with higher scores indicating better global health status and quality of life.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in General Self-Efficacy Assessed by the ASKU
Lasso di tempo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

General self-efficacy is assessed using the Allgemeine Selbstwirksamkeit Kurzskala (ASKU). The mean score ranges from 1 to 5, with higher scores indicating greater general self-efficacy.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Depressive Symptoms Assessed by the Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Depressive symptoms are assessed using the 9-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Patient-Reported Symptoms Assessed by the PRO-CTCAE
Lasso di tempo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Symptoms and treatment-related adverse effects are assessed using pre-specified items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Selected symptom attributes, including frequency, severity, and interference with daily activities, are analyzed at the item level according to the respective PRO-CTCAE response scales. Each attribute is scored from 0 to 4, with higher scores indicating greater symptom frequency, severity, or interference and therefore a worse outcome. No overall summary score is calculated.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Leisure-Time Physical Activity Assessed by the Godin Leisure-Time Exercise Questionnaire
Lasso di tempo: Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Leisure-time physical activity is assessed using the Godin Leisure-Time Exercise Questionnaire. The primary metric is the Leisure Score Index, calculated as (9 × weekly frequency of strenuous activity) + (5 × weekly frequency of moderate activity) + (3 × weekly frequency of mild activity). The Leisure Score Index has a minimum value of 0 and no predefined maximum value because the reported weekly activity frequencies are not capped. Higher scores indicate greater leisure-time physical activity and therefore a better outcome.

Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Sitting Time Assessed Using Items From the International Physical Activity Questionnaire (IPAQ)
Lasso di tempo: Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Sedentary behavior is assessed using selected sitting-time items from the International Physical Activity Questionnaire (IPAQ). The outcome is average daily sitting time, expressed in minutes per day, with a theoretical range from 0 to 1,440 minutes per day. Higher values indicate more time spent sitting and therefore a worse outcome.

Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Social and Occupational Reintegration After Hospital Discharge
Lasso di tempo: 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Reintegration is assessed using the study-specific RESTART Reintegration Questionnaire following allogeneic hematopoietic stem cell transplantation (HSCT). Items on return to everyday life, social integration, and ability to manage important daily activities are rated from 1 ("not at all") to 5 ("completely"); higher scores indicate better reintegration. Reintegration into employment, education, studies, or a comparable regular activity is rated from 1 to 5, with higher scores indicating better reintegration; 0 indicates "not applicable" and is not interpreted as a lower score. Current employment/education status is assessed categorically. An open-ended item assesses factors facilitating or hindering reintegration. Items are analyzed separately; no overall summary score is calculated.

13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Occurrence and Severity of Graft-Versus-Host Disease
Lasso di tempo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

Acute and/or chronic graft-versus-host disease (GvHD) is obtained from routine clinical records. GvHD status at hospital discharge and occurrence or progression during follow-up are documented, including clinically assessed grade or stage where applicable.

Hospital discharge (T1) through 12 months after hospital discharge (T4)
Incidence of Infections
Lasso di tempo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

Clinically documented infections occurring after hospital discharge are obtained from routine clinical records. The number of infections per participant is recorded and infections are additionally characterized by type and severity.

Hospital discharge (T1) through 12 months after hospital discharge (T4)
Number of Rehospitalizations
Lasso di tempo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

The number of rehospitalizations occurring after hospital discharge is obtained from routine clinical records. Duration and reason for rehospitalization are additionally documented.

Hospital discharge (T1) through 12 months after hospital discharge (T4)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in White Blood Cell Count
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

White blood cell count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Absolute Neutrophil Count
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Absolute neutrophil count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Absolute Lymphocyte Count
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Absolute lymphocyte count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Platelet Count
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Platelet count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Hemoglobin Concentration
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Hemoglobin concentration is obtained from routine clinical laboratory data and expressed in g/dL. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in C-Reactive Protein Concentration
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

C-reactive protein (CRP) concentration is obtained from routine clinical laboratory data, where available, and expressed in mg/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Measurable Residual Disease Status
Lasso di tempo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Measurable residual disease (MRD) status is obtained from routine clinical assessments using disease-specific methods and documented as positive or negative. Quantitative results are additionally recorded where available.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Donor Chimerism
Lasso di tempo: From allogeneic HSCT through 12 months after hospital discharge (T4), as available from routine clinical care

Donor chimerism is obtained from routine clinical assessments following allogeneic HSCT and expressed as percentage donor chimerism, where available.

From allogeneic HSCT through 12 months after hospital discharge (T4), as available from routine clinical care
Time to Hematologic Recovery
Lasso di tempo: From allogeneic HSCT through hematologic recovery, as documented during follow-up through 12 months after hospital discharge (T4)

Hematologic recovery following allogeneic HSCT is assessed from routine clinical laboratory data. Time to hematologic recovery is documented in days according to the definitions used in routine transplant care.

From allogeneic HSCT through hematologic recovery, as documented during follow-up through 12 months after hospital discharge (T4)
Exercise Intervention Adherence Rate
Lasso di tempo: During the 12-week intervention period

Adherence is calculated as the percentage of prescribed RESTART exercise sessions completed by participants assigned to the exercise intervention group. Higher percentages indicate greater adherence.

During the 12-week intervention period
Number of Completed Exercise Sessions
Lasso di tempo: During the 12-week intervention period

The total number of completed RESTART exercise sessions is recorded for participants assigned to the exercise intervention group. Sessions are additionally categorized as individual in-person, supervised online, or home-based sessions.

During the 12-week intervention period
Exercise Training Frequency
Lasso di tempo: During the 12-week intervention period

Exercise training frequency is calculated as the mean number of completed RESTART exercise sessions per week among participants assigned to the exercise intervention group.

During the 12-week intervention period
Participant Dropout Rate
Lasso di tempo: From enrollment through 12 months after hospital discharge (T4)

The dropout rate is calculated as the proportion of enrolled participants who discontinue study participation before completion of the final follow-up assessment. Reasons for dropout are documented descriptively.

From enrollment through 12 months after hospital discharge (T4)
Number of Participants With Adverse Events During the Intervention or Control Period
Lasso di tempo: Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

The number of participants experiencing at least one adverse event during the intervention or control period is recorded. Adverse events are additionally characterized by type, severity, and possible relationship to the exercise intervention.

Hospital discharge (T1) through 13 weeks after hospital discharge (T2)
Number of Participants With Serious Adverse Events During the Intervention or Control Period
Lasso di tempo: Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

The number of participants experiencing at least one serious adverse event during the intervention or control period is recorded. Serious adverse events are additionally characterized by type, severity, and possible relationship to the exercise intervention.

Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Miriam Goette, PD Dr. rer. medic., University Hospital, Essen

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2026

Completamento primario (Stimato)

30 settembre 2029

Completamento dello studio (Stimato)

1 luglio 2030

Date di iscrizione allo studio

Primo inviato

30 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 settembre 2026

Primo Inserito (Effettivo)

9 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi